+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

The Next Generation Sequencing (NGS) Markets in China

  • ID: 5412111
  • Report
  • August 2021
  • Region: China
  • 365 Pages
  • AcuBiz Consulting Sdn Bhd
An in-depth look at the NGS market growth trends in the clinical as well as non-clinical segments in China (2021-2026 period), along with the impact of COVID-19 in 2020

FEATURED COMPANIES

  • 10x Genomics, Inc
  • Agilent Technologies
  • Berry Genomics Co Ltd
  • Burning Rock Medical
  • Da An Gene Co., Ltd.
  • HaploX Biotechnology

This report analyses the market trends influencing various NGS market segments in China. It also analyses the global market trends, which have an impact in China's NGS market and also compares China's market trends with the trends in key global markets. It covers a detailed analysis of the impact of COVID-19 in each market segment.


This report segments China’s NGS market with respect to methods, applications, and product as well as service types. The drivers and restraints of segments are evaluated for estimating market sizes, forecasts and COVID-19 impact. The profiles of leading players in the global as well as Chinese markets are studied in detail along with their response to the pandemic and impact on their NGS revenues. The report also includes a detailed analysis of the regulatory, intellectual property, and the reimbursement landscapes in China that play a major role in shaping the NGS market, particularly related to the clinical diagnostics end-use segments. The report has a total of 365 pages, which includes 79 tables.


Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 10x Genomics, Inc
  • Agilent Technologies
  • Berry Genomics Co Ltd
  • Burning Rock Medical
  • Da An Gene Co., Ltd.
  • HaploX Biotechnology

1. Market Overview

NGS Workflow and Leading Products in the Market

  • Library Preparation and Amplification
  • Sequencing
  • Data Analysis    

NGS Market Trends    

  • Market Drivers    
    • Technological Advancements
    • Declining Costs
    • Precision Medicine Focus
    • Increasing Demand from Clinical Applications Segments
    • Growing Investments in Companion Diagnostics (CDX) Development

  • Market Restraints    
    • High Costs Compared to Alternative Genomic Platforms    
    • Lack of Effective Software Solutions for Data Management and Downstream Analysis    
    • NGS Data Management, Interpretation and Sharing: Ethical and Legal Issues    
    • Lack of Geneticists    

Influence of China’s Regulatory Landscape on Its NGS Market    

  • Government Initiatives Relevant for NGS Market    
    • Five-Year Plans (FYP)    
    • Healthy China 2030 (HC 2030)    
    • Investments for Genome Databases    
    • Made in China 2025    

  • Regulations and Expert Consensus on Genetic Testing in China    
  • Table 1: Regulatory Agencies Relevant for Genetic Testing    
  • Table 2: Approval of NGS-Based Diagnostics: Regulatory Agencies Involved    
  • Regulatory Pathways Relevant for NGS-Based Diagnostic Products    
  • Genomic Material and Genomic Data Sharing Policy of China    
  • Table 3: Highlights of the Human Genetic Resources Regulation in China Relevant for Foreign Organizations and Collaborators    
  • Lab Developed Tests (LDTS)    
  • Independent Clinical Laboratories (Icls) Offering NGS Services    
  • Table 4: Regulatory Requirements for Clinical Genetic Testing Services    
  • Negative List    
  • Regulatory Pathway for CDX    
  • Table 5:  Regulatory Guidelines Relevant for CDX by Nmpa    

Health Insurance Landscape in China and Its Influence on NGS Market    

  • Social Health Insurance Schemes in China    
  • Table 6. The Social Health Insurance Schemes (SHIS) in China.    
  • Private Health Insurance    
  • Insurance for Genome Sequencing Services    
    • Partnerships Between Insurance Companies and NGS Test Service Providers    

  • The NGS Market Landscape in China    
    • Partnerships Focusing on NGS Platforms and Assays    

NGS Market Size and Growth Forecasts    

  • Table 7: the NGS Market Size and Forecast in China (USD, Million)    

2. NGS Markets in China by Methods    

Targeted Genome Sequencing and Resequencing    

  • Table 8: Selected List of NGS-Based Gene Panel Tests for Clinical Diagnostics in China    

Whole Genome Sequencing (WGS)    

  • WGS-Based Clinical Diagnostics Tests in China    
  • Large-Scale WGS Studies in China    
  • Table 9: Selected List of Large-Scale WGS Projects in China    

Whole Exome Sequencing (Wes)    

RNA-Seq    

  • RNA-Seq: An Assessment of the Global Market Trends    
  • Table 10: Selected List of Companies Offering RNA-Seq Library Preparation Kits    
    • mRNA-Seq    
    • Non-Coding RNA-Seq    
    • Single-Cell RNA-Seq (SCRNA-Seq)    

  • Table 11: Selected List of the Cell Isolation and Library Preparation Platforms for SCRNA-Seq    
  • Table 12: Selected List of SCRNA-Seq Data Analysis Products    
  • Growth of RNA-Seq Demand in China    
  • Table 13: RNA-Seq Demand for Research in China (2017-2021)    
  • Transcriptomics Moving from Microarrays to RNA-Seq    

Other NGS Methods    

The Market Size and Growth Trends of the Leading NGS Methods    

  • Table 14: the NGS Market Size and Forecast in China by Method (USD, Million)    

3. NGS Markets in China by Products and Services    

Instruments    

  • Single Cell Sequencing    
  • Table 15: Popular NGS Platforms in the Chinese Market    
  • Emergence Domestic Gene Sequencers Challenge Existing OEM Models    
    • NGS Systems Demand Growing in China’s Hospital Segment Triggered by Covid-19    

  • NGS Workflow Automation Products    
  • Table 16: Selected List of Vendors Facilitating NGS Automation in China    

Consumables and Accessories    

  • Table 17: Selected List of NGS Library Preparation Products for Research Use    

Bioinformatics Tools for NGS    

  • Primary Data Analysis    
  • Secondary Data Analysis    
  • Tertiary Data Analysis    
  • Table 18: Commonly Used Bioinformatic Tools for NGS: for Primary, Secondary, and Tertiary Data Analysis    
    • Role of Cloud Computing    
    • Key Challenges of NGS Data Analysis Players    
      • High Costs    
      • PCR Amplification Bias    
      • Data Confidentiality Concerns    
      • Translation of Data into Actionable Insights    
      • Integration of Data for Comparison With Results Derived from Different Platforms    

    • The Growing NGS Data Analysis Demand for Clinical Diagnostics in China    
    • NGS Data Analysis in China: Activities of Key Players    

  • NGS Service Providers in China    
  • Table 19: Selected List of Leading NGS Service Providers in China    

NGS Market Size and Growth Trends in China by Products and Services    

  • Table 20: the NGS Market Size and Forecasts in China by Products and Services (USD, Million)    

4. NGS Markets in China by Application Segments    

Clinical Diagnostics    

  • Oncology    
  • Table 21: Leading Cancer Types in China: Incidences & Deaths    
    • Cancer Survival Rates in China    
    • Government Initiatives for Cancer Prevention in China    

  • Table 22: Selected List of Cancer Prevention and Control Measures in China    
    • Healthy China Program (2019-30): Focus on Cancer    
    • Challenges of Implementing Cancer Prevention Strategies in China    
    • Genetic Testing in Oncology Sector: Prescription Trends    
    • Regulations Influencing NGS-Based Cancer Diagnosis in China    

  • Table 23: Selected List of Medical Associations That Influence Cancer Diagnostics Guidelines in China    
    • NGS-Based CDX Tests for Cancer in China: Regulations and Expert Consensus    
      • Guidelines for Restricted Use Drugs and Related CDX    

    • NGS-Based Cancer Diagnostics: An Overview of the Global Market    
    • The Role of NGS in China’s Cancer Diagnostics    

  • Table 24: Molecular Diagnostics Platforms Used for Companion Diagnostics for Different Cancer Therapies    
  • Table 25: NGS- Based Cancer Companion Diagnostics Approved by China’s NMPA    
    • The Growing Demand for Gene Panel Tests for Cancer Diagnostics    
    • The Prospects for NGS-Based Early Tumor Screening in China
    • NGS as a Complimentary Platform
    • Leading NGS Players in China’s Oncology Sector and Their Revenue Models    
      • Comparison of the Revenue Models of Burning Rock, Amoy Diagnostics, and Berry Genomics    

    • Partnerships of Global Players With Domestic Companies    

  • Table 26: NGS-Based Cancer Diagnostics in China: Partnerships Between Global Players and Domestic Companies    
    • NGS Demand for Cancer Diagnostics in China: Market Trends    

  • Reproductive Health Diagnostics    
    • The Rising Global Demand for NIPT    

  • Table 27: Typical Diseases and Aneuploidies Tested by NIPT Assays    
  • Table 28: Selected List of NGS-Based NIPT Tests in the Global Market    
    • An Assessment of the Ip Landscape of NGS Platforms in the Global NIPT Market    
    • The Ip Landscape of NIPT in China    
    • Rising Investments in the New-Born and Prenatal Testing Markets    
    • Prenatal Testing Insurance Coverage Status: China Vs Other Leading Markets    
    • Regulations Influencing the NGS Demand in Reproductive Health Diagnostics    
      • Regulations on New-Born and Prenatal Testing    
      • Regulations on Preimplantation Genetic Testing (PGT)    

    • Reproductive Health Diagnostics Market Trends in China    
      • The Growing Demand for NGS-Based NIPT    
      • The Emerging Preimplantation Genetic Testing (PGT) Segment in China    
      • New-Born Testing and Carrier Screening Segments: Opportunities for NGS Players in China    
        • New-Born Testing    
        • Carrier Screening    

      • Collaborations and Partnerships in the Reproductive Health Diagnostics Segments    


  • Table 29: Selected List of Partnerships of NGS Companies in China in the Field of Reproductive Health Diagnostics    
    • Availability of NGS-Based Reproductive Health Tests    

  • Table 30: Selected List of NGS-Based Reproductive Health Tests Available in China    
    • NGS Demand in Other Clinical Diagnostics Segments    
    • Infectious Diseases    
      • Covid-19 Testing    
      • Tuberculosis    

    • HLA Typing    
    • Hereditary Diseases    

Direct-To-Consumer Genetic Testing (DTC-GT) Application Segment    

  • Alternative Regulatory Pathways: Trends in the Global as Well as China’s DTC-GT Markets    
    • An Assessment of the Legal Framework for DTC-GT in China    

  • Table 31: the Evolving Regulatory Landscape Influencing China’s DTC-GT Market    
    • Informed Consent in China    

  • Logistics Channels of DTC-GT in China    
  • Revenue Generation Models: Global Market Trends Vs Emerging Models in China    
    • Lack of Genetic Counsellors Offering New Opportunities to Data Analysis Start-Ups    

  • Key Focus Areas of DTC-GT in China    
    • Talent Screening    

  • Status of DTC Genetic Testing in China    
  • Table 32: Selected Players in China Offering DTC-GT Services    

NGS for Research Applications in China    

  • Academic Research    
  • Table 33: Selected List of Prominent Research Centres Active in NGS Research    
  • Large-Scale Genome Projects in China    
  • Table 34: Selected List of Large-Scale NGS-Based Genome Projects in China    
  • Chinese Genome Databases    
  • Table 35: Selected List of Organizations Developing Human Genome Databases in China    
  • Industry R&D    
  • Table 36: Selected List of Industry R&D Partnerships Signed by NGS Companies in China    

Other Emerging NGS Application Segments: Food Testing, Forensics, Etc.    

Market Size and Forecasts of NGS in Key Application Segments in China    

  • Table 37: the NGS Market Size and Forecasts in China by Application Segments (2021-2026; USD, Million)    

5. Company Profiles    

10X Genomics, Inc    

  • Products and Services    
  • Table 38: Selected List of NGS Products Offered by 10X Genomics    
  • Response to Covid-19 Pandemic    
  • Acquisitions and Partnerships    
  • Table 39: Selected List of Partnerships and Acquisitions of 10X Genomics    
  • Activities in the China Market    

23Mofang    

Adicon (Hangzhou Adicon Clinical Laboratories, Inc.)    

  • Table 40: the List of Cities Under the Service Network of Adicon    
  • Activities in the NGS Field    
  • Table 41: a Selected List of NGS Services Offered by Adicon    

Agilent Technologies    

  • NGS Products Offered by Agilent Technologies    
  • Partnerships and Collaborations    
  • Table 42: Selected List of Partnerships of Agilent Technologies in the Last 5 Years    
  • Impact of Covid-19 on Agilent’S NGS Business    
  • Activities in China’S NGS Market    

Amoy Diagnostics Co Ltd.    

  • Products and Services Offered by Amoydx    
  • Table 43: Selected Assays and Services Offered by Amoydx    
  • Collaborations/Partnerships    
  • Table 44: Selected List of Collaborations Signed by Amoydx    
  • Response to Covid-19 Pandemic    

Annoroad Gene Technology Beijing Co Ltd    

  • Activities in the NGS Field    

Basecare Medical (Suzhou Basecare Medical Device Co. Ltd.)    

  • An Emerging Art Solutions Provider    

Berry Genomics Co Ltd    

  • Investments and Collaborations    
  • Table 45: Selected List of Partnership Agreements Signed by Berry Genomics    
  • Sequencing Services Offered by Berry Genomics    
  • Table 46: NGS Platforms Used for Offering Sequencing Services by Berry Genomics    
  • Assays and Services Offered by Berry Genomics    
  • Table 47: Assays and Services Offered by Berry Genomics    
  • Response to Covid-19 Pandemic    

BGI Group    

  • BGI Genomics Co Ltd and MGI Tech    
  • Table 48: Sequencers Produced and Marketed by the BGI Group    
  • Table 49: NGS-Based Assays and Services Provided by BGI Group    
  • Partnerships and Collaborations    
  • Table 50 : Selected List of Partnerships BGI Group*    
  • Response to Covid-19    

Burning Rock Medical    

  • Table 51: Selected List of Collaborations of Burning Rock Related to the NGS Market    

Capitalbio Corporation    

  • Activities in the NGS Market    
    • Capitalbio Technology Co. Ltd (Capitalbio Tech)    

  • Table 52: Selected List of NGS Services Offered by Capitalbio Tech    
    • Capitalbio Genomics Co. Ltd. (Capitalbio Genomics)    

  • Table 53: Selected List of NGS Services Offered by Capitalbio Genomics    
    • Capitalbio Diagnostic Laboratory (Capitalbio Diagnostic)    

  • Table 54: the Service Network of Capitalbio Diagnostic Across China    
  • Table 55: Selected List of NGS-Based Clinical Testing Services Offered by Capitalbio Diagnostics    

Da An Gene Co. Ltd.    

  • Guangzhou Darui Biotechnology Co. Ltd. (Darui Biotech;达瑞生物)    
  • Table 56: Selected List of NGS-Based Tests Offered by Darui Biotech    

Dian Diagnostics Group Co. Ltd.    

  • Table 57: the List of Provinces in China Covered Under the Service Network of Dian    
  • NGS-Based Business Activities    
  • Table 58: Selected List of NGS Services Offered by Dian    

Geneseeq Technology Inc    

  • Products and Services    
  • Table 59: Selected List of NGS-Based Assays and Services Offered by Geneseeq Technology    
  • Collaborations/Partnerships    
  • Response to Covid-19 Pandemic    

Genetron Health (Beijing) Co. Ltd    

  • Table 60: Funding Raised by Genetron Health    
  • Collaborations and Partnerships    
  • Products & Services    
  • Table 61: Selected List of NGS-Based Products of Genetron Health    

Haplox Biotechnology    

  • Partnerships and Collaborations    
  • Products and Services Offered by Haplox    

Jellyfish Gene (Beijing Jellyfish Technology Co. Ltd.)    

Kingmed Diagnostics (Guangzhou Kingmed Diagnostics Group Co. Ltd.)    

  • Table 62: the List of Cities Under the Service Network of Kingmed    
  • Business Activities in the Field of NGS    
  • Table 63: Selected List of NGS Services Offered by Kingmed    

Illumina    

  • Expanding Consumer Segments    
  • NGS Business – Strategies, Products, and Services    
  • Table 64: Selected List of Sequencing Systems Offered by Illumina    
  • Table 65: Selected List of Assays Offered by Illumina    
  • Response to Covid-19 Pandemic    
  • Focus on Innovation and Related Investments    
  • Clinical Diagnostics Strategies    
  • Table 66: Selected List of Partnerships Targeting Diagnostics Applications    
  • Activities in China’S NGS Market    
    • Collaborations With China-Based Companies    

  • Table 67: Selected List of Partners of Illumina in the Field of Clinical Diagnostics in China    

Novogene Co. Ltd.    

  • Table 68: Novogene’S Service Network in China    
  • Table 69: NGS-Based Services for Research Applications Offered by Novogene    

Oxford Nanopore Technologies    

  • Table 70: Sequencers Offered by Oxford Nanopore Technologies    
  • Response to Covid-19 Pandemic    
  • Partnerships and Collaborations    
  • Table 71: Selected List of Recent Partnerships of Oxford Nanopore Technologies    
  • Activities in the Chinese Market    

Pacific Biosciences    

  • Table 72: Selected List of the Products Offered by Pacbio    
  • Partnerships and Collaborations    
  • Table 73: Selected List of Partnerships of Pacbio    
  • Impact of Covid-19 Pandemic    
  • Activities in China’S NGS Market    

Qi Carbon Technology Co Ltd (Qc Technology)    

  • Collaborations/Partnerships    
  • Technology Offered by Qc Technology    
  • Table 74: Nanopore Gene Sequencing Technology Products Offered by Qc Technology    
  • Response to Covid-19 Pandemic    

Spacegen (Xiamen Spacegen Co. Ltd.)    

Thermo Fisher Scientific Inc.    

  • Response to Covid-19 Pandemic    
  • Partnerships and Acquisitions    
  • Table 75: Selected Partnerships and Acquisitions of Thermo Fisher (2017-2020)    
  • NGS Products and Services    
  • Table 76: NGS Instruments Offered by Thermo Fisher Scientific    
  • Table 77: Selected List of NGS-Based Assays and Services of Thermo Fisher Scientific    
  • Thermo Fisher Scientific in China’S NGS Market    

Tiangen Biotech Co. Ltd.    

  • Response to Covid-19 Pandemic    
  • Tiangen Biotech NGS Portfolio    

Transgen Biotech (Beijing Transgen Biotech Co. Ltd.)    

  • Response to Covid-19 Pandemic    

Turtle Technology (Shanghai Turtle Technology Co. Ltd.)    

Wegene    

  • Collaborations/Partnerships    
  • Table 78: Selected List of Collaborations Signed by Wegene    
  • Assays and Services Offered by Wegene    
  • Table 79: Selected List of Assays and Services Offered by Wegene    

Zhongke Zixin (Beijing Zhongke Zixin    Technology Co. Ltd.)    

6. Glossary    

7. Disclaimer    

List of Tables

Table 1: Regulatory Agencies Relevant for Genetic Testing    
Table 2: Approval of NGS-Based Diagnostics: Regulatory Agencies Involved    
Table 3: Highlights of the Human Genetic Resources Regulation in China Relevant for Foreign Organizations and Collaborators    
Table 4: Regulatory Requirements for Clinical Genetic Testing Services    
Table 5:  Regulatory Guidelines Relevant for CDX by NMPA    
Table 6: the Social Health Insurance Schemes (SHIS) in China.    
Table 7: the NGS Market Size and Forecast in China (USD, Million)    
Table 8: Selected List of NGS-Based Gene Panel Tests for Clinical Diagnostics in China    
Table 9: Selected List of Large-Scale WGS Projects in China    
Table 10: Selected List of Companies Offering RNA-Seq Library Preparation Kits    
Table 11: Selected List of the Cell Isolation and Library Preparation Platforms for SCRNA-Seq    
Table 12: Selected List of SCRNA-Seq Data Analysis Products    
Table 13: RNA-Seq Demand for Research in China (2017-2021)    
Table 14: the NGS Market Size and Forecast in China by Method (USD, Million)    
Table 15: Popular NGS Platforms in the Chinese Market    
Table 16: Selected List of Vendors Facilitating NGS Automation in China    
Table 17: Selected List of NGS Library Preparation Products for Research Use    
Table 18: Commonly Used Bioinformatic Tools for NGS: for Primary, Secondary, and Tertiary Data Analysis    
Table 19: Selected List of Leading NGS Service Providers in China    
Table 20: the NGS Market Size and Forecasts in China by Products and Services (USD, Million)    
Table 21: Leading Cancer Types in China: Incidences & Deaths    
Table 22: Selected List of Cancer Prevention and Control Measures in China    
Table 23: Selected List of Medical Associations That Influence Cancer Diagnostics Guidelines in China    
Table 24: Molecular Diagnostics Platforms Used for Companion Diagnostics for Different Cancer Therapies    
Table 25: NGS- Based Cancer Companion Diagnostics Approved by China’S Nmpa    
Table 26: NGS-Based Cancer Diagnostics in China: Partnerships Between Global Players and Domestic Companies    
Table 27: Typical Diseases and Aneuploidies Tested by NIPT Assays    
Table 28: Selected List of NGS-Based NIPT Tests in the Global Market    
Table 29: Selected List of Partnerships of NGS Companies in China in the Field of Reproductive Health Diagnostics    
Table 30: Selected List of NGS-Based Reproductive Health Tests Available in China    
Table 31: the Evolving Regulatory Landscape Influencing China’S DTC-GT Market    
Table 32: Selected Players in China Offering DTC-GT Services    
Table 33: Selected List of Prominent Research Centres Active in NGS Research    
Table 34: Selected List of Large-Scale NGS-Based Genome Projects in China    
Table 35: Selected List of Organizations Developing Human Genome Databases in China    
Table 36: Selected List of Industry R&D Partnerships Signed by NGS Companies in China    
Table 37: the NGS Market Size and Forecasts in China by Application Segments (2021-2026; USD, Million)    
Table 38: Selected List of NGS Products Offered by 10X Genomics    
Table 39: Selected List of Partnerships and Acquisitions of 10X Genomics    
Table 40: the List of Cities Under the Service Network of Adicon    
Table 41: a Selected List of NGS Services Offered by Adicon    
Table 42: Selected List of Partnerships of Agilent Technologies in the Last 5 Years    
Table 43: Selected Assays and Services Offered by Amoydx    
Table 44: Selected List of Collaborations Signed by Amoydx    
Table 45: Selected List of Partnership Agreements Signed by Berry Genomics    
Table 46: NGS Platforms Used for Offering Sequencing Services by Berry Genomics    
Table 47: Assays and Services Offered by Berry Genomics    
Table 48: Sequencers Produced and Marketed by the BGI Group    
Table 49: NGS-Based Assays and Services Provided by BGI Group    
Table 50: Selected List of Partnerships BGI Group*    
Table 51: Selected List of Collaborations of Burning Rock Related to the NGS Market    
Table 52: Selected List of NGS Services Offered by Capitalbio Tech    
Table 53: Selected List of NGS Services Offered by Capitalbio Genomics    
Table 54: the Service Network of Capitalbio Diagnostic Across China    
Table 55: Selected List of NGS-Based Clinical Testing Services Offered by Capitalbio Diagnostics    
Table 56: Selected List of NGS-Based Tests Offered by Darui Biotech    
Table 57: the List of Provinces in China Covered Under the Service Network of Dian    
Table 58: Selected List of NGS Services Offered by Dian    
Table 59: Selected List of NGS-Based Assays and Services Offered by Geneseeq Technology    
Table 60: Funding Raised by Genetron Health    
Table 61: Selected List of NGS-Based Products of Genetron Health    
Table 62: the List of Cities Under the Service Network of Kingmed    
Table 63: Selected List of NGS Services Offered by Kingmed    
Table 64: Selected List of Sequencing Systems Offered by Illumina    
Table 65: Selected List of Assays Offered by Illumina    
Table 66: Selected List of Partnerships Targeting Diagnostics Applications    
Table 67: Selected List of Partners of Illumina in the Field of Clinical Diagnostics in China    
Table 68: Novogene’S Service Network in China    
Table 69: NGS-Based Services for Research Applications Offered by Novogene    
Table 70: Sequencers Offered by Oxford Nanopore Technologies    
Table 71: Selected List of Recent Partnerships of Oxford Nanopore Technologies    
Table 72: Selected List of the Products Offered by Pacbio    
Table 73: Selected List of Partnerships of Pacbio    
Table 74: Nanopore Gene Sequencing Technology Products Offered by Qc Technology    
Table 75: Selected Partnerships and Acquisitions of Thermo Fisher (2017-2020)    
Table 76: NGS Instruments Offered by Thermo Fisher Scientific    
Table 77: Selected List of NGS-Based Assays and Services of Thermo Fisher Scientific    
Table 78: Selected List of Collaborations Signed by Wegene    
Table 79: Selected List of Assays and Services Offered by Wegene


Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 10x Genomics, Inc
  • Agilent Technologies
  • Berry Genomics Co Ltd
  • Burning Rock Medical
  • Da An Gene Co., Ltd.
  • HaploX Biotechnology

China was part of the Human Genome Project that was completed in 2001. Since then, there has been significant investments in the genomics field by the government as well as different market players. This has helped to maintain a critical mass of skilled manpower who could drive genomics research and its applications in the country. 


Globally, the genomics field is witnessing massive changes during the past few decades. Technologies such as PCR and microarrays have fundamentally changed the landscape of several application segments. Currently, NGS is influencing similar changes, at an accelerated pace. Some of the key factors driving the acceptance of NGS by various end-use segments include improvements in affordability, ease of use, and data analysis capabilities. There has been a significant reduction in the cost of sequencing per base during the past five years. China has also witnessed a similar trend in the domestic market. In fact, the leading NGS players in China offer NGS products and services at highly competitive rates compared to their counterparts in developed countries. Favourable government policies as well as financial support have played a crucial role in their success, in addition to the relatively lower manpower costs available in the domestic market. 


Automated NGS workflow solutions have played a major role in the adoption of NGS in many targeted markets. Integration of the sequencing process with automated sample preparation, library preparation and data analysis steps has helped laboratories to scale up their NGS services, which assisted in reducing their services fees. The advancement in data analysis solutions is another factor that has enabled adoption of NGS by end-users including those involved in non-clinical application areas such as food testing, and forensics. 


Significant challenges still exist for NGS that limit their growth potentials. For instance, cost is still much higher compared to the other genomic platforms. In addition to the capital costs associated with establishing NGS workflows, the laboratories also need to budget for high recurring costs for expensive consumables as well as reagents. High costs are also involved in hiring and retaining skilled workforce for NGS operations. The costs for maintaining large data storage and data analysis facilities can also increase the budget significantly. 


In terms of application segments, clinical diagnostics applications are expected to drive the demand for NGS in China. The advent of simpler benchtop sequencers has played a critical role in improving precision medicine awareness. As more NGS-based clinical diagnostics enter the market, the demand for NGS-based clinical testing is expected to grow at a CAGR of 25.2 percent during the forecast period. 


The Chinese government has done significant investments to promote NGS. One of the major application segments benefitted from these investments is precision medicine. Many on-going large scale NGS-based genomics projects support this goal and drive the demand for NGS in the research segments. NGS-based methods are being used by industry R&D groups for various applications including clinical research and companion diagnostics development. Another key application area with significant growth potentials is Direct-to-Consumer genetic testing (DTC-GT). As other application segments, this segment was affected significantly in the early part of 2020 as the demand declined due to the pandemic. Together, non-clinical segments are expected to drive the demand for NGS at a CAGR of 12.2 percent during the forecast period. Overall, non-clinical segments account for about 64 percent of China’s NGS market at present. The share of this segment is expected to decline to 51 percent by 2026.


In terms of NGS methods, targeted sequencing based on gene panels are estimated to account for over 37 percent of China’s NGS market. It is expected to grow at a CAGR of 10 percent during the forecast period. Another NGS method expected to grow fast is whole genome sequencing, which is expected to grow at a CAGR of 19.4 percent. Currently, this method segment accounts for over 40 percent of the market. RNA-sequencing is another NGS method expected to have high growth during the forecast period.


Within the products and services segments, consumables are estimated to account for over 55 percent of the NGS market in China, while services including bioinformatics solutions is the second largest segment accounting for about 23 percent of the market. The demand for NGS consumables is expected to grow at a CAGR of about 20 percent during the forecast period and account for over 63 percent of the market by 2026.


Overall, the NGS market in China is expected to grow at a CAGR of 17.6 percent between 2021 and 2026. Though COVID-19 pandemic impacted the growth during the initial months in 2020, the market segments have recovered. The growth is expected to continue across all the market segments as acceptance of NGS increase among the end-users as NGS become more affordable and simpler.


Note: Product cover images may vary from those shown
  • 10x Genomics, Inc    
  • 23Mofang    
  • Adicon (Hangzhou Adicon Clinical Laboratories, Inc.)
  • Agilent Technologies    
  • Amoy Diagnostics Co Ltd.    
  • Annoroad Gene Technology Beijing Co Ltd
  • Basecare Medical (Suzhou Basecare Medical Device Co. Ltd.)
  • Berry Genomics Co Ltd
  • BGI Group
  • Burning Rock Medical    
  • CapitalBio Corporation    
  • Da An Gene Co., Ltd.    
  • Guangzhou Darui Biotechnology Co., Ltd. (DARUI Biotech;达瑞生物)
  • Dian Diagnostics Group Co., Ltd.    
  • Geneseeq Technology Inc    
  • Genetron Health (Beijing) Co., Ltd    
  • HaploX Biotechnology    
  • Jellyfish Gene (Beijing Jellyfish Technology Co., Ltd.)    
  • KingMed Diagnostics (Guangzhou KingMed Diagnostics Group Co., Ltd.)
  • Illumina    
  • Novogene Co., Ltd.    
  • Oxford Nanopore Technologies
  • Pacific Biosciences    
  • Qi Carbon Technology Co Ltd (QC Technology)    
  • Spacegen (Xiamen Spacegen Co., Ltd.)    
  • Thermo Fisher Scientific Inc.    
  • Tiangen Biotech Co., Ltd.    
  • TransGen Biotech (Beijing TransGen Biotech Co., Ltd.)    
  • Turtle Technology (Shanghai Turtle Technology Co., Ltd.)    
  • WeGene    
  • Zhongke Zixin (Beijing Zhongke Zixin Technology Co., Ltd.)
Note: Product cover images may vary from those shown